BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX ...

BioNTech (BNTX) is back in focus after recent trading left the stock at a last close of US$88.08, with investors weighing its cancer and infectious disease pipeline against current revenue and ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to ...

BioNTech sails into ASCO with two clinical readouts that underscore its pivot toward oncology beyond vaccines, even as the stock trades under mid-year pressure and investors weigh the pace of the ...

View BioNTech SE Sponsored ADR BNTX stock quote prices, financial information, real-time forecasts, and company news from CNN.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

BioNTech rolled out an extensive clinical dataset at this year’s ASCO conference, yet its shares continue to trade well below their highs — a disconnect that has frustrated bulls and left the company ...

BioNTech SE has agreed to acquire British artificial intelligence (AI) startup InstaDeep for up to 562 million pounds ($682 ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...